Enoxaparin Sodium
Enoxaparin Sodium is a pharmaceutical drug with 21 clinical trials. Currently 2 active trials ongoing. Historical success rate of 88.9%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
13
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
84.2%
16 of 19 finished
15.8%
3 ended early
2
trials recruiting
21
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients
Clinical Trials (21)
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients
A Single-Dose Trial to Examine the Within Subject Variability of Clexane® in Healthy Adults Under Fasting Conditions
Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 21